Additional file 5: Table S4. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

Open link

Publication date

February 2018

DOI

10.6084/m9.figshare.5900692.v1

Abstract

Changes in the level of GPT, BUN, and creatinine by treatment with LL28 in mice. (PDF 109Â kb

Extracted data

We use cookies to provide a better user experience.

Data Protection

Additional file 5: Table S4. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

Open link

Publication date

February 2018

DOI

10.6084/m9.figshare.5900692.v1

Abstract

Changes in the level of GPT, BUN, and creatinine by treatment with LL28 in mice. (PDF 109Â kb

Extracted data

Ho Chan (3766132)
Mark Konijnenberg (3763234)
Tamara Daniels (3766123)
Monique Nysus (561399)
Mehran Makvandi (3766129)
Erik de Blois (3763228)
Wouter Breeman (3763231)
Robert Atcher (3766126)
Marion de Jong (121558)
Jeffrey Norenberg (315686)

November 2016

Improved safety and efficacy of 213Bi-DOTATATE targeted alpha therapy of somatostatin receptor-expre...

Additional file 1: of Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

Johanna Dalmo (3766627)
Johan Spetz (770437)
Mikael Montelius (3766621)
Britta Langen (770438)
Yvonne Arvidsson (94503)
Henrik Johansson (519182)
Toshima Parris (3762496)
Khalil Helou (561963)
Bo WĂ¤ngberg (3766618)
Ola Nilsson (94507)
Maria Ljungberg (3766624)
Eva Forssell-Aronsson (658141)

January 2017

Table S1. Anti-tumor effect of 177Lu-octreotate on GOT1-bearing nude mice. (DOCX 21Â kb

Additional file 1: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella (475207)
Andrea Ravelli (5022788)
Claudia Fumarola (475204)
Silvia La Monica (475199)
Graziana Digiacomo (5022785)
Andrea Cavazzoni (475206)
Roberta Alfieri (79926)
Alessandra Biondi (5022779)
Daniele Generali (426339)
Mara Bonelli (475205)
Pier Petronini (5022782)

March 2018

Table S1. Sensitivity of TNBC cells to PI3K/mTOR inhibitors. HCC38 cells and MDA-MB-231 cells were t...

Additional file 3: Table S2. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

The IC50 values showing the inhibitory effect of LL28 on the viability of a panel of human lung canc...

Additional file 4: Table S3. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

The IC50 values showing the inhibitory effect of LL28 on the anchorage-dependent colony -forming abi...

Additional file 1: of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

Synthesis and characterization of compounds 3a-f, 4a-d and their intermediates. (PDF 2667Â kb

Additional file 5: of MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Yoshimi Greer (6374504)
Samuel Gilbert (6374507)
Brunilde Gril (202357)
Rajesh Narwal (4425985)
Danielle Peacock Brooks (6374510)
David Tice (3173028)
Patricia Steeg (6374513)
Stanley Lipkowitz (253942)

February 2019

Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...

Additional file 2: of New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells

Sonoko Atsumi (1965367)
Chisato Nosaka (1965364)
Hayamitsu Adachi (1666837)
Tomoyuki Kimura (1896370)
Yoshihiko Kobayashi (3418922)
Hisashi Takada (1520299)
Takumi Watanabe (704540)
Shun-ichi Ohba (704535)
Hiroyuki Inoue (91878)
Manabu Kawada (704534)
Masakatsu Shibasaki (704542)
Masabumi Shibuya (622249)

July 2016

I-Ertredin suppressed NIH3T3/EGFRvIII tumorigenicity. NIH3T3/EGFRvIII cells were subcutaneously tran...

Additional file 4: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Gianfranco Caselli (1913095)
Albino Bonazzi (4901713)
Marco Lanza (1913101)
Flora Ferrari (2174444)
Daniele Maggioni (4901728)
Cristian Ferioli (4901725)
Roberto Giambelli (4901701)
Eleonora Comi (4901716)
Silvia Zerbi (4901704)
Marco Perrella (4901731)
Ornella Letari (3017292)
Elena Di Luccio (4901710)
Milena Colovic (4901734)
Stefano Persiani (4901719)
Tiziano Zanelli (4901722)
Laura Mennuni (2174448)
Tiziana Piepoli (4901737)
Lucio Rovati (4901707)

March 2018

Data table showing the effect of repeated administration of CR6086, MTX and their combination in art...

Additional file 3: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Gianfranco Caselli (1913095)
Albino Bonazzi (4901713)
Marco Lanza (1913101)
Flora Ferrari (2174444)
Daniele Maggioni (4901728)
Cristian Ferioli (4901725)
Roberto Giambelli (4901701)
Eleonora Comi (4901716)
Silvia Zerbi (4901704)
Marco Perrella (4901731)
Ornella Letari (3017292)
Elena Di Luccio (4901710)
Milena Colovic (4901734)
Stefano Persiani (4901719)
Tiziano Zanelli (4901722)
Laura Mennuni (2174448)
Tiziana Piepoli (4901737)
Lucio Rovati (4901707)

March 2018

Data table showing cytokine serum concentrations (pg/ml) of samples determined from 3-PLEX (MSD) in ...

Additional file 4: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

Roberto Rosato (5722406)
Daniel Dávila-González (5722409)
Dong Choi (3578132)
Wei Qian (56612)
Wen Chen (30046)
Anthony Kozielski (5722412)
Helen Wong (241565)
Bhuvanesh Dave (147341)
Jenny Chang (3489839)

September 2018

Effects of the anti-CTLA-4 immune checkpoint inhibitor antibody ipilimumab against MC1 PDXs implante...

Additional file 2: Figure S2. of Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

Qing-Bai She (90195)
Sofia Gruvberger-Saal (69453)
Matthew Maurer (3447629)
Yilun Chen (837411)
Mervi Jumppanen (69452)
Tao Su (409037)
Meaghan Dendy (3447626)
Ying-Ka Lau (3447623)
Lorenzo Memeo (129955)
Hugo Horlings (40754)
Marc van de Vijver (27203)
Jorma Isola (41977)
Hanina Hibshoosh (631904)
Neal Rosen (78497)
Ramon Parsons (26084)
Lao Saal (3447632)

August 2016

Chronic treatment with gefitinib and PWT-458, alone or in combination, does not cause eight loss in ...

Additional file 1: Table S1. of Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL

Isabelle Bartram (276596)
Ulrike Erben (252359)
Jutta Ortiz-Tanchez (3579101)
Katja Blunert (3579104)
Cornelia Schlee (105296)
Martin Neumann (276593)
Sandra Heesch (276598)
Claudia Baldus (3579098)

October 2015

Probe sets in the IGF1-R signatures that are over-expressed in the high IGF1-R group. Table S2. Prob...

Additional file 1: of Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Ho Chan (3766132)
Mark Konijnenberg (3763234)
Tamara Daniels (3766123)
Monique Nysus (561399)
Mehran Makvandi (3766129)
Erik de Blois (3763228)
Wouter Breeman (3763231)
Robert Atcher (3766126)
Marion de Jong (121558)
Jeffrey Norenberg (315686)

November 2016

Improved safety and efficacy of 213Bi-DOTATATE targeted alpha therapy of somatostatin receptor-expre...

Additional file 1: of Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

Johanna Dalmo (3766627)
Johan Spetz (770437)
Mikael Montelius (3766621)
Britta Langen (770438)
Yvonne Arvidsson (94503)
Henrik Johansson (519182)
Toshima Parris (3762496)
Khalil Helou (561963)
Bo WĂ¤ngberg (3766618)
Ola Nilsson (94507)
Maria Ljungberg (3766624)
Eva Forssell-Aronsson (658141)

January 2017

Table S1. Anti-tumor effect of 177Lu-octreotate on GOT1-bearing nude mice. (DOCX 21Â kb

Additional file 1: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella (475207)
Andrea Ravelli (5022788)
Claudia Fumarola (475204)
Silvia La Monica (475199)
Graziana Digiacomo (5022785)
Andrea Cavazzoni (475206)
Roberta Alfieri (79926)
Alessandra Biondi (5022779)
Daniele Generali (426339)
Mara Bonelli (475205)
Pier Petronini (5022782)

March 2018

Table S1. Sensitivity of TNBC cells to PI3K/mTOR inhibitors. HCC38 cells and MDA-MB-231 cells were t...

Additional file 3: Table S2. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

The IC50 values showing the inhibitory effect of LL28 on the viability of a panel of human lung canc...

Additional file 4: Table S3. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

The IC50 values showing the inhibitory effect of LL28 on the anchorage-dependent colony -forming abi...

Additional file 1: of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Ho Lee (453255)
Phuong Pham (3140775)
Seung Hyun (1422880)
Byungyeob Baek (4862170)
Byungjin Kim (4862176)
Yunha Kim (771542)
Hye-Young Min (4862173)
Jeeyeon Lee (1456894)
Ho-Young Lee (1612351)

February 2018

Synthesis and characterization of compounds 3a-f, 4a-d and their intermediates. (PDF 2667Â kb

Yoshimi Greer (6374504)
Samuel Gilbert (6374507)
Brunilde Gril (202357)
Rajesh Narwal (4425985)
Danielle Peacock Brooks (6374510)
David Tice (3173028)
Patricia Steeg (6374513)
Stanley Lipkowitz (253942)

February 2019

Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...

Sonoko Atsumi (1965367)
Chisato Nosaka (1965364)
Hayamitsu Adachi (1666837)
Tomoyuki Kimura (1896370)
Yoshihiko Kobayashi (3418922)
Hisashi Takada (1520299)
Takumi Watanabe (704540)
Shun-ichi Ohba (704535)
Hiroyuki Inoue (91878)
Manabu Kawada (704534)
Masakatsu Shibasaki (704542)
Masabumi Shibuya (622249)

July 2016

I-Ertredin suppressed NIH3T3/EGFRvIII tumorigenicity. NIH3T3/EGFRvIII cells were subcutaneously tran...

Additional file 4: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Gianfranco Caselli (1913095)
Albino Bonazzi (4901713)
Marco Lanza (1913101)
Flora Ferrari (2174444)
Daniele Maggioni (4901728)
Cristian Ferioli (4901725)
Roberto Giambelli (4901701)
Eleonora Comi (4901716)
Silvia Zerbi (4901704)
Marco Perrella (4901731)
Ornella Letari (3017292)
Elena Di Luccio (4901710)
Milena Colovic (4901734)
Stefano Persiani (4901719)
Tiziano Zanelli (4901722)
Laura Mennuni (2174448)
Tiziana Piepoli (4901737)
Lucio Rovati (4901707)

March 2018

Data table showing the effect of repeated administration of CR6086, MTX and their combination in art...

Additional file 3: of Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Gianfranco Caselli (1913095)
Albino Bonazzi (4901713)
Marco Lanza (1913101)
Flora Ferrari (2174444)
Daniele Maggioni (4901728)
Cristian Ferioli (4901725)
Roberto Giambelli (4901701)
Eleonora Comi (4901716)
Silvia Zerbi (4901704)
Marco Perrella (4901731)
Ornella Letari (3017292)
Elena Di Luccio (4901710)
Milena Colovic (4901734)
Stefano Persiani (4901719)
Tiziano Zanelli (4901722)
Laura Mennuni (2174448)
Tiziana Piepoli (4901737)
Lucio Rovati (4901707)

March 2018

Data table showing cytokine serum concentrations (pg/ml) of samples determined from 3-PLEX (MSD) in ...

Additional file 4: of Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

Roberto Rosato (5722406)
Daniel Dávila-González (5722409)
Dong Choi (3578132)
Wei Qian (56612)
Wen Chen (30046)
Anthony Kozielski (5722412)
Helen Wong (241565)
Bhuvanesh Dave (147341)
Jenny Chang (3489839)

September 2018

Effects of the anti-CTLA-4 immune checkpoint inhibitor antibody ipilimumab against MC1 PDXs implante...

Additional file 2: Figure S2. of Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer

Qing-Bai She (90195)
Sofia Gruvberger-Saal (69453)
Matthew Maurer (3447629)
Yilun Chen (837411)
Mervi Jumppanen (69452)
Tao Su (409037)
Meaghan Dendy (3447626)
Ying-Ka Lau (3447623)
Lorenzo Memeo (129955)
Hugo Horlings (40754)
Marc van de Vijver (27203)
Jorma Isola (41977)
Hanina Hibshoosh (631904)
Neal Rosen (78497)
Ramon Parsons (26084)
Lao Saal (3447632)

August 2016

Chronic treatment with gefitinib and PWT-458, alone or in combination, does not cause eight loss in ...

Additional file 1: Table S1. of Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL

Isabelle Bartram (276596)
Ulrike Erben (252359)
Jutta Ortiz-Tanchez (3579101)
Katja Blunert (3579104)
Cornelia Schlee (105296)
Martin Neumann (276593)
Sandra Heesch (276598)
Claudia Baldus (3579098)

October 2015

Probe sets in the IGF1-R signatures that are over-expressed in the high IGF1-R group. Table S2. Prob...

Additional file 1: of Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Ho Chan (3766132)
Mark Konijnenberg (3763234)
Tamara Daniels (3766123)
Monique Nysus (561399)
Mehran Makvandi (3766129)
Erik de Blois (3763228)
Wouter Breeman (3763231)
Robert Atcher (3766126)
Marion de Jong (121558)
Jeffrey Norenberg (315686)

November 2016

Improved safety and efficacy of 213Bi-DOTATATE targeted alpha therapy of somatostatin receptor-expre...

Additional file 1: of Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

Johanna Dalmo (3766627)
Johan Spetz (770437)
Mikael Montelius (3766621)
Britta Langen (770438)
Yvonne Arvidsson (94503)
Henrik Johansson (519182)
Toshima Parris (3762496)
Khalil Helou (561963)
Bo WĂ¤ngberg (3766618)
Ola Nilsson (94507)
Maria Ljungberg (3766624)
Eva Forssell-Aronsson (658141)

January 2017

Table S1. Anti-tumor effect of 177Lu-octreotate on GOT1-bearing nude mice. (DOCX 21Â kb

Additional file 1: of The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella (475207)
Andrea Ravelli (5022788)
Claudia Fumarola (475204)
Silvia La Monica (475199)
Graziana Digiacomo (5022785)
Andrea Cavazzoni (475206)
Roberta Alfieri (79926)
Alessandra Biondi (5022779)
Daniele Generali (426339)
Mara Bonelli (475205)
Pier Petronini (5022782)

March 2018

Table S1. Sensitivity of TNBC cells to PI3K/mTOR inhibitors. HCC38 cells and MDA-MB-231 cells were t...

Additional file 5: Table S4. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Abstract

Extracted data

Additional file 5: Table S4. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Abstract

Extracted data

Related items

Related items